Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBITDA: 2012-2024

Historic EBITDA for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to -$171.8 million.

  • Ocular Therapeutix's EBITDA fell 49.35% to -$68.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.8 million, marking a year-over-year decrease of 77.57%. This contributed to the annual value of -$171.8 million for FY2024, which is 108.52% down from last year.
  • Per Ocular Therapeutix's latest filing, its EBITDA stood at -$171.8 million for FY2024, which was down 108.52% from -$82.4 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's EBITDA peaked at -$62.8 million during FY2020, and registered a low of -$171.8 million during FY2024.
  • Its 3-year average for EBITDA is -$110.9 million, with a median of -$82.4 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first grew by 27.24% in 2020, then tumbled by 108.52% in 2024.
  • Over the past 5 years, Ocular Therapeutix's EBITDA (Yearly) stood at -$62.8 million in 2020, then fell by 24.17% to -$78.0 million in 2021, then declined by 0.79% to -$78.7 million in 2022, then declined by 4.74% to -$82.4 million in 2023, then slumped by 108.52% to -$171.8 million in 2024.